OVERUSE OF ASPIRIN, INPATIPRONE, AND PreVENTERS: A TALE OF TWO COUNTRIES

Inappropriate asthma therapy: a tale of two countries

In 2007, 3,954 UK patients were included in the cohort, with a mean age of 21.7 years (77% children and 73% adults) and ±52.2% males. In 2013, 14,050 patients met our inclusion criteria, with a mean age of 24.2 years (22% children and 78% adults) with ±51.8% males.

In 2007, 5,010 French patients were studied. The cohort included 50.8% males (35% children and 66% adults), with a mean age of 22.1 years. In 2013, 3,657 patients were included, (35.1% children and 64.5% adults), ±51.8, and with a mean age of 21.4 years.

UK AVERAGE (2007 vs 2013)

In 2007 and 2013 patients were predominantly prescribed LABA (32% 32%), ICS (29% 31%), and LABA without ICS (9% 9%) and LABA with ICS (2% 3%).

In 2007 and 2013 patients were predominantly prescribed LABA (22% 23%), ICS (22% 22%), and LABA without ICS (36% 36%) and LABA with ICS (2% 3%).

UK AVERAGE (2007 vs 2013)

In 2007 and 2013 patients were predominantly prescribed LABA (32% 32%), ICS (29% 31%), and LABA without ICS (9% 9%) and LABA with ICS (2% 3%).

In 2007 and 2013 patients were predominantly prescribed LABA (22% 23%), ICS (22% 22%), and LABA without ICS (36% 36%) and LABA with ICS (2% 3%).

RESULTS (1)

In 2007, 2013, and 2013, respectively, 24%, 35%, and 35% of patients were prescribed a single-component LABA inhaled corticosteroid (ICS) preventer treatment.

RESULTS (2)

In 2007, 2013, and 2013, respectively, 24%, 35%, and 35% of patients were prescribed a single-component LABA inhaled corticosteroid (ICS) preventer treatment.

In 2007, 2013, and 2013, respectively, 24%, 35%, and 35% of patients were prescribed a single-component LABA inhaled corticosteroid (ICS) preventer treatment.

In 2007, 2013, and 2013, respectively, 24%, 35%, and 35% of patients were prescribed a single-component LABA inhaled corticosteroid (ICS) preventer treatment.

In 2007, 2013, and 2013, respectively, 24%, 35%, and 35% of patients were prescribed a single-component LABA inhaled corticosteroid (ICS) preventer treatment.